相似文献
1
Aggregation promoting C-terminal truncation of alpha-synuclein is a normal cellular process and is enhanced by the familial Parkinson's disease-linked mutations.
Proc Natl Acad Sci U S A. 2005 Feb 8;102(6):2162-7. doi: 10.1073/pnas.0406976102. Epub 2005 Jan 31.
2
Human alpha-synuclein-harboring familial Parkinson's disease-linked Ala-53 --> Thr mutation causes neurodegenerative disease with alpha-synuclein aggregation in transgenic mice.
Proc Natl Acad Sci U S A. 2002 Jun 25;99(13):8968-73. doi: 10.1073/pnas.132197599.
3
Stabilization of alpha-synuclein protein with aging and familial parkinson's disease-linked A53T mutation.
J Neurosci. 2004 Aug 18;24(33):7400-9. doi: 10.1523/JNEUROSCI.1370-04.2004.
4
Physiology and pathophysiology of alpha-synuclein. Cell culture and transgenic animal models based on a Parkinson's disease-associated protein.
Ann N Y Acad Sci. 2000;920:33-41. doi: 10.1111/j.1749-6632.2000.tb06902.x.
5
Antiapoptotic property of human alpha-synuclein in neuronal cell lines is associated with the inhibition of caspase-3 but not caspase-9 activity.
J Neurochem. 2005 Jun;93(6):1542-50. doi: 10.1111/j.1471-4159.2005.03146.x.
6
The novel Parkinson's disease linked mutation G51D attenuates in vitro aggregation and membrane binding of α-synuclein, and enhances its secretion and nuclear localization in cells.
Hum Mol Genet. 2014 Sep 1;23(17):4491-509. doi: 10.1093/hmg/ddu165. Epub 2014 Apr 11.
7
Fibrillization of alpha-synuclein and tau in familial Parkinson's disease caused by the A53T alpha-synuclein mutation.
Exp Neurol. 2004 Jun;187(2):279-88. doi: 10.1016/j.expneurol.2004.01.007.
8
Distinct cleavage patterns of normal and pathologic forms of alpha-synuclein by calpain I in vitro.
J Neurochem. 2003 Aug;86(4):836-47. doi: 10.1046/j.1471-4159.2003.01878.x.
9
Axonal transport of human alpha-synuclein slows with aging but is not affected by familial Parkinson's disease-linked mutations.
J Neurochem. 2004 Jan;88(2):401-10. doi: 10.1046/j.1471-4159.2003.02166.x.
10
C-terminal α-synuclein truncations are linked to cysteine cathepsin activity in Parkinson's disease.
J Biol Chem. 2019 Jun 21;294(25):9973-9984. doi: 10.1074/jbc.RA119.008930. Epub 2019 May 15.
引用本文的文献
1
Differential role of C-terminal truncations on alpha-synuclein pathology and Lewy body formation.
NPJ Parkinsons Dis. 2025 Aug 26;11(1):261. doi: 10.1038/s41531-025-01084-y.
2
Soluble and Insoluble Lysates from the Human A53T Mutant α-Synuclein Transgenic Mouse Model Induces α-Synucleinopathy Independent of Injection Site.
Int J Mol Sci. 2025 Jun 28;26(13):6254. doi: 10.3390/ijms26136254.
3
Alpha-synuclein modulates the positioning of endolysosomes in melanoma cells.
Hum Mol Genet. 2025 Aug 21;34(17):1433-1445. doi: 10.1093/hmg/ddaf096.
4
Rational selection of the monoclonal α-synuclein antibody amlenetug (Lu AF82422) for the treatment of α-synucleinopathies.
NPJ Parkinsons Dis. 2025 May 22;11(1):132. doi: 10.1038/s41531-024-00849-1.
5
Monomers, Dimers, and Oligomers of Pyroglutamate-Modified α-Synuclein Fragments Exhibit Distinct Biophysical Characteristics.
ACS Chem Neurosci. 2025 May 21;16(10):1919-1936. doi: 10.1021/acschemneuro.5c00106. Epub 2025 Apr 30.
6
A fragment of Calpain-1 cleaved α-Synuclein quantified in serum is upregulated in patients with Parkinson's disease.
Sci Rep. 2025 Apr 9;15(1):12081. doi: 10.1038/s41598-025-92726-x.
7
Ultrasensitive Protein Aggregate Quantification Assays for Neurodegenerative Diseases on the Simoa Platform.
Anal Chem. 2025 Jan 14;97(1):290-299. doi: 10.1021/acs.analchem.4c04188. Epub 2024 Dec 24.
8
Microglia Process α-Synuclein Fibrils and Enhance their Pathogenicity in a TREM2-Dependent Manner.
Adv Sci (Weinh). 2025 Feb;12(7):e2413451. doi: 10.1002/advs.202413451. Epub 2024 Dec 12.
9
MJF-14 proximity ligation assay detects early non-inclusion alpha-synuclein pathology with enhanced specificity and sensitivity.
NPJ Parkinsons Dis. 2024 Nov 29;10(1):227. doi: 10.1038/s41531-024-00841-9.
10
α-Synuclein pathology as a target in neurodegenerative diseases.
Nat Rev Neurol. 2025 Jan;21(1):32-47. doi: 10.1038/s41582-024-01043-w. Epub 2024 Nov 28.
本文引用的文献
1
Abeta deposition is associated with enhanced cortical alpha-synuclein lesions in Lewy body diseases.
Neurobiol Aging. 2005 Aug-Sep;26(8):1183-92. doi: 10.1016/j.neurobiolaging.2004.10.006. Epub 2004 Dec 28.
2
Stabilization of alpha-synuclein protein with aging and familial parkinson's disease-linked A53T mutation.
J Neurosci. 2004 Aug 18;24(33):7400-9. doi: 10.1523/JNEUROSCI.1370-04.2004.
3
Clearance of alpha-synuclein oligomeric intermediates via the lysosomal degradation pathway.
J Neurosci. 2004 Feb 25;24(8):1888-96. doi: 10.1523/JNEUROSCI.3809-03.2004.
4
Axonal transport of human alpha-synuclein slows with aging but is not affected by familial Parkinson's disease-linked mutations.
J Neurochem. 2004 Jan;88(2):401-10. doi: 10.1046/j.1471-4159.2003.02166.x.
5
Yeast cells provide insight into alpha-synuclein biology and pathobiology.
Science. 2003 Dec 5;302(5651):1772-5. doi: 10.1126/science.1090439.
6
alpha-Synuclein locus triplication causes Parkinson's disease.
Science. 2003 Oct 31;302(5646):841. doi: 10.1126/science.1090278.
7
Distinct cleavage patterns of normal and pathologic forms of alpha-synuclein by calpain I in vitro.
J Neurochem. 2003 Aug;86(4):836-47. doi: 10.1046/j.1471-4159.2003.01878.x.
8
Role of alpha-synuclein carboxy-terminus on fibril formation in vitro.
Biochemistry. 2003 Jul 22;42(28):8530-40. doi: 10.1021/bi027363r.
9
Parkinson's disease and related alpha-synucleinopathies are brain amyloidoses.
Ann N Y Acad Sci. 2003 Jun;991:107-10. doi: 10.1111/j.1749-6632.2003.tb07468.x.
10
Zeroing in on the pathogenic form of alpha-synuclein and its mechanism of neurotoxicity in Parkinson's disease.
Biochemistry. 2003 Jul 8;42(26):7871-8. doi: 10.1021/bi030086j.
Zotero 插件